Prognostic utility of gamma-glutamyl transpeptidase to platelet ratio in patients with solitary hepatitis B virus-related hepatocellular carcinoma after hepatectomy

Figure 1 Flow diagram of the propensity score analysis for this study. GPR: Gamma-glutamyl transpeptidase-to-platelet ratio; RCS: Restricted cubic spline; HCC: Hepatocellular carcinoma; BCLC: Barcelona Clinic Liver Cancer.

Figure 2 Violin plot analysis comparing the gamma-glutamyl transpeptidase-to-platelet ratio levels among hepatitis B virus-related hepatocellular carcinoma and other 7 non-hepatocellular carcinoma groups. Pairwise comparisons were performed by Games-Howell test, and P value was adjusted by Benjamini-Hochberg methods.

Figure 3 The balance test of propensity score matching and KaplanMeier analysis between gamma-glutamyl transpeptidase-to-platelet ratio level and prognosis of solitary hepatitis B virus-related hepatocellular carcinoma cohort. A: Distribution of propensity values before and after propensity score matching (PSM); B: Absolute standardized differences in covariates between solitary hepatocellular carcinoma (HCC) patients with gamma-glutamyl transpeptidase-to-platelet ratio (GPR) ≤ 0.2 and GPR > 0.2, before and after PSM; C and D: Kaplan-Meier survival curves of overall survival in patients with solitary HCC before and after PSM; E and F: Kaplan-Meier survival curves of RFS in patients with solitary HCC before and after PSM. PSM: Propensity score matching; GPR: Gamma-glutamyl transpeptidase-to-platelet ratio; BMI: Body mass index; HR: Hazard ratio; AFP: Alpha-fetoprotein; TB: Total bilirubin; ALB: Albumin; HBV: Hepatitis B virus; MVI: Microvascular imaging.

Figure 4 Subgroup analyses for gamma-glutamyl transpeptidase-to-platelet ratio level and combined analyses of gamma-glutamyl transpeptidase-to-platelet ratio levels and variables in overall survival and recurrence-free survival of solitary hepatitis B virus-related hepatocellular carcinoma. A: Subgroup analyses for overall survival (OS) and recurrence-free survival (RFS); B: Combined analyses with tumor size, cirrhosis, alpha-fetoprotein (AFP), and microvascular imaging (MVI) for OS; C: Combined analyses with tumor size, cirrhosis, AFP, and MVI for RFS. GPR: Gamma-glutamyl transpeptidase-to-platelet ratio; HR: Hazard ratio; OS: Overall survival; BMI: Body mass index; HR: Hazard ratio; AFP: Alpha-fetoprotein; HBV: Hepatitis B virus; BCLC: Barcelona Clinic Liver Cancer; F: Female; M: Male.

Figure 5 The association between gamma-glutamyl transpeptidase-to-platelet ratio and death/recurrence risk and Kaplan-Meier stratified analysis between gamma-glutamyl transpeptidase-to-platelet ratio levels and prognosis in the solitary hepatitis B virus-related hepatocellular carcinoma cohort. A: The restricted cubic spline curves of gamma-glutamyl transpeptidase-to-platelet ratio levels. The risk was adjusted by age, cirrhosis, hepatitis B virus-DNA, tumor size, microvascular imaging, and infiltrative growth; B: Kaplan-Meier survival curves of overall survival (OS) and recurrence-free survival (RFS) in patients with solitary hepatocellular carcinoma (HCC) before propensity score matching (PSM); C: Triangle plot and absolute standardized differences adjustment of three groups; D: Kaplan-Meier survival curves of OS and RFS in patients with solitary HCC after PSM. OS: Overall survival; PSM: Propensity score matching; GPR: Gamma-glutamyl transpeptidase-to-platelet ratio; MVI: Microvascular imaging; HBV: Hepatitis B virus; BCLC: Barcelona Clinic Liver Cancer; BMI: Body mass index; HR: Hazard ratio; AFP: Alpha-fetoprotein.

Figure 6 Prognostic nomograms for solitary hepatitis B virus-related hepatocellular carcinoma. A: Nomogram plot and calibration curves for overall survival; B: Nomogram plot and calibration curves for recurrence-free survival. AFP: Alpha-fetoprotein; HBV: Hepatitis B virus; MVI: Microvascular imaging; BCLC: Barcelona Clinic Liver Cancer; GPR: Gamma-glutamyl transpeptidase-to-platelet ratio; RFS: Recurrence-free survival; OS: Overall survival; F: Female; M: Male.